

**Supplemental Table 3. Overall, intracranial, and extracranial efficacy in cohorts EXP4 and EXP5**

	<b>2 prior ALK TKIs (EXP4)</b>	<b>3 prior ALK TKIs (EXP5)</b>
<b>OVERALL</b>		
<i>N</i>	65	46
ORR, <i>n</i> (%)	26 (40.0)	17 (37.0)
95% CI	28.0–52.9	23.2–52.5
Best overall response, <i>n</i> (%)		
Complete response	2 (3.1)	0
Partial response	24 (36.9)	17 (37.0)
Stable disease/ no response	22 (33.8)	14 (30.4)
Progressive disease	11 (16.9)	11 (23.9)
Indeterminate	6 (9.2)	4 (8.7)
Duration of objective response, <sup>a</sup> months		
<i>N</i>	26	17
Median	15.1	7.0
95% CI	5.6–26.3	4.2–11.0
Progression-free survival, months		
Median	7.3	5.5
95% CI	4.2–11.1	3.9–8.2

	<b>2 prior ALK TKIs (EXP4)</b>	<b>3 prior ALK TKIs (EXP5)</b>
<b>INTRACRANIAL WITH ≥1 MEASURABLE CNS LESION</b>		
<i>N</i>	24	24
IC-ORR, <i>n</i> (%)	15 (62.5)	11 (45.8)
95% CI	40.6–81.2	25.6–67.2
Best overall response, <i>n</i> (%)		
Complete response	6 (25.0)	4 (16.7)
Partial response	9 (37.5)	7 (29.2)
Stable disease/ no response	7 (29.2)	9 (37.5)
Progressive disease	2 (8.3)	2 (8.3)
Indeterminate	0	2 (8.3)
Duration of IC objective response, <sup>a</sup> months		
<i>N</i>	15	11
Median	14.5	8.0
95% CI	5.8–NE	5.6–15.0
<b>EXTRACRANIAL</b>		
<i>N</i>	65	46
EC-ORR, <i>n</i> (%)	25 (38.5)	17 (37.0)
95% CI	26.7–51.4	23.2–52.5
Best overall response, <i>n</i> (%)		
Complete response	2 (3.1)	2 (4.3)
Partial response	23 (35.4)	15 (32.6)
Stable disease/ no response	26 (40.0)	16 (34.8)

	<b>2 prior ALK TKIs (EXP4)</b>	<b>3 prior ALK TKIs (EXP5)</b>
Progressive disease	8 (12.3)	9 (19.6)
Indeterminate	6 (9.2)	4 (8.7)
Duration of EC objective response, <sup>a</sup> months		
<i>N</i>	25	17
Median	7.1	9.7
95% CI	5.5–33.3	5.6–NE

ALK, anaplastic lymphoma kinase; CI, confidence interval; EC, extracranial; EXP, expansion cohort; IC, intracranial; NE, not estimable; ORR, objective response rate; TKI, tyrosine kinase inhibitor.

<sup>a</sup> Kaplan–Meier estimates; CIs were derived using the Brookmeyer Crowley method.